- Home
- LEU vs HUMA Comparison
LEU vs HUMA Comparison
Compare LEU & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEU
- HUMA
- Stock Information
- Founded
- LEU 1998
- HUMA 2004
- Country
- LEU United States
- HUMA United States
- Employees
- LEU N/A
- HUMA N/A
- Industry
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- LEU Industrials
- HUMA Health Care
- Exchange
- LEU Nasdaq
- HUMA Nasdaq
- Market Cap
- LEU 4.2B
- HUMA 250.2M
- IPO Year
- LEU 1998
- HUMA N/A
- Fundamental
- Price
- LEU $229.72
- HUMA $1.53
- Analyst Decision
- LEU Buy
- HUMA Strong Buy
- Analyst Count
- LEU 11
- HUMA 8
- Target Price
- LEU $194.80
- HUMA $10.88
- AVG Volume (30 Days)
- LEU 1.2M
- HUMA 2.9M
- Earning Date
- LEU 10-27-2025
- HUMA 11-07-2025
- Dividend Yield
- LEU N/A
- HUMA N/A
- EPS Growth
- LEU 10.12
- HUMA N/A
- EPS
- LEU 6.16
- HUMA N/A
- Revenue
- LEU $436,900,000.00
- HUMA $818,000.00
- Revenue This Year
- LEU $3.52
- HUMA N/A
- Revenue Next Year
- LEU $8.01
- HUMA $1,619.38
- P/E Ratio
- LEU $37.34
- HUMA N/A
- Revenue Growth
- LEU 12.72
- HUMA N/A
- 52 Week Low
- LEU $39.19
- HUMA $1.15
- 52 Week High
- LEU $264.90
- HUMA $6.77
- Technical
- Relative Strength Index (RSI)
- LEU 59.33
- HUMA 42.17
- Support Level
- LEU $214.00
- HUMA $1.45
- Resistance Level
- LEU $243.80
- HUMA $1.53
- Average True Range (ATR)
- LEU 14.62
- HUMA 0.09
- MACD
- LEU 3.69
- HUMA 0.04
- Stochastic Oscillator
- LEU 75.43
- HUMA 51.72
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.